

I-Mab, Jiangsu Nhwa team up with Biodextris, Brigham for treating neuro disorders

10 April 2019 | News

I-Mab and Nhwa will provide financial, technical, regulatory, and business support



I-Mab Biopharma (I-Mab), a clinical stage biotech company based in Shanghai with an exclusive focus on the development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases, and Jiangsu Nhwa Pharmaceutical (Nhwa), a company devoted to central nervous system (CNS) drug development, manufacturing and service have recently entered into collaborative research agreement with world-renowned scientists and clinicians at the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital and Biodextris, a Montreal-based biologics contract development and manufacturing organization, to jointly develop a novel immuno-stimulatory therapy for neurologic disorders by harnessing the natural power of the immune system.

Under the terms of the agreement, parties will combine their resources and expertise in basic science, translational research, clinical development, manufacturing and commercialization, to accelerate the translation of innovative immunotherapy into the clinic for the most challenging diseases with the highest unmet medical needs.

The Brigham team will be responsible for preclinical development including biomarker discovery and validation, as well as early clinical studies. Biodextris will be responsible for CMC development and manufacturing of clinical materials. I-Mab and Nhwa will provide financial, technical, regulatory, and business support for the preclinical as well as clinical development, and potentially future commercialization.